ARHGEF12 Genotype and Netarsudil Response in Glaucoma Subjects

Clinical data from a study investigating the association between the ARHGEF12 genetic variant and therapeutic response to the Rho-kinase inhibitor netarsudil in glaucoma. The dataset includes analysis of 1,844 African ancestry subjects with primary open-angle glaucoma (POAG), with a treatment subset of 66 subjects (114 eyes). The work was authored by Anusha Mamidipaka and last updated in May 2026.

Use Cases

• Analyze the relationship between ARHGEF12 genotype and intraocular pressure (IOP) reduction based on the 12-month treatment outcomes described.
• Compare baseline glaucoma severity and ocular phenotypes across genetic carrier groups as outlined in the study methods.
• Evaluate the statistical significance of genotype on other ocular measures like cup-to-disc ratio and retinal nerve fiber layer thickness mentioned in the results.
• Assess the potential for pharmacogenetic prediction of Rho-kinase inhibitor response based on the described biological rationale and exploratory findings.

Strengths

• Includes a substantial cohort of 1,844 African ancestry subjects with POAG for baseline analysis.
• Provides specific, quantified results for IOP reduction (e.g., -1.77 ± 5.06 mmHg in non-carriers) and response rates (29.8% vs 34.6%).
• Released under a permissive CC-BY-4.0 license, facilitating reuse and redistribution.

Limitations

• The primary data is a 16.1 KB DOCX file, suggesting the dataset is likely a summary table or document rather than raw, structured patient-level data.
• Column-level documentation is absent; field semantics must be inferred after download.
• The study's treatment cohort is relatively small (66 subjects), and the authors note the results are preliminary and exploratory.

Provenance

Source

figshare

Collection Method

Clinical study analysis comparing demographic, ocular phenotypes, and treatment response across genetic groups using generalized estimating equations.

Time Range

The study period is not specified, but data covers a 12-month treatment follow-up.

Freshness

Last updated 2026-05-08 05:48:18; freshness should be verified.

Geography

Subjects are of African ancestry; specific geographic locations are not provided.